1. Home
  2. DUOT vs GANX Comparison

DUOT vs GANX Comparison

Compare DUOT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DUOT
  • GANX
  • Stock Information
  • Founded
  • DUOT 1990
  • GANX 2017
  • Country
  • DUOT United States
  • GANX United States
  • Employees
  • DUOT N/A
  • GANX N/A
  • Industry
  • DUOT Computer Software: Prepackaged Software
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DUOT Technology
  • GANX Health Care
  • Exchange
  • DUOT Nasdaq
  • GANX Nasdaq
  • Market Cap
  • DUOT 66.3M
  • GANX 53.8M
  • IPO Year
  • DUOT N/A
  • GANX 2021
  • Fundamental
  • Price
  • DUOT $7.53
  • GANX $1.72
  • Analyst Decision
  • DUOT Strong Buy
  • GANX Strong Buy
  • Analyst Count
  • DUOT 2
  • GANX 5
  • Target Price
  • DUOT $12.50
  • GANX $8.20
  • AVG Volume (30 Days)
  • DUOT 143.5K
  • GANX 305.2K
  • Earning Date
  • DUOT 08-12-2025
  • GANX 08-07-2025
  • Dividend Yield
  • DUOT N/A
  • GANX N/A
  • EPS Growth
  • DUOT N/A
  • GANX N/A
  • EPS
  • DUOT N/A
  • GANX N/A
  • Revenue
  • DUOT $11,162,390.00
  • GANX N/A
  • Revenue This Year
  • DUOT $294.36
  • GANX N/A
  • Revenue Next Year
  • DUOT $43.87
  • GANX N/A
  • P/E Ratio
  • DUOT N/A
  • GANX N/A
  • Revenue Growth
  • DUOT 89.27
  • GANX N/A
  • 52 Week Low
  • DUOT $2.03
  • GANX $0.89
  • 52 Week High
  • DUOT $9.27
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • DUOT 48.78
  • GANX 49.29
  • Support Level
  • DUOT $7.55
  • GANX $1.55
  • Resistance Level
  • DUOT $8.20
  • GANX $1.79
  • Average True Range (ATR)
  • DUOT 0.57
  • GANX 0.16
  • MACD
  • DUOT 0.00
  • GANX -0.00
  • Stochastic Oscillator
  • DUOT 56.84
  • GANX 44.53

About DUOT Duos Technologies Group Inc.

Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains while they are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: